Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Shareholder Meeting (November 2010)
32 slides from Actinogen Medical's shareholder meeting presentation, Nov 30, 2010
Slide 1: For personal use only
For personal use only
Slide 2: Actinogen and its soil bacteria
For personal use only Actinogen isolates a group of gram positive bacteria mainly from the soils of Western Australia. These bacteria are unique in that they have a wide ranging ability to mobilise metabolic pathways and to utilise many unusual sources of nutrients. They produce many bioactive molec
Slide 3: Staffing and Board reporting 2009-2010
For personal use only 2009-2010 3 FULL TIME STAFF 3 PART TIME STAFF Weekly brainstorming meetings Monthly report goes to all Board members Quarterly; Half yearly and Annual Reports All go to Board members to enable Board to assess progress and formulate policies
Slide 4: Screening programmes overview
For personal use only Antibiotic Agriculture WA screening programme soils Anti cancer Plastic and Actinomycetes screening paper are isolated digesting Anti fungal and purified screening Iron Isolates are Fine leaching classified, stored chemicals at subzero temps
Slide 5: Isolate purification and library
For personal use only This section continues to be the area in which all new isolates are purified and classified. They are recorded along with a range of biochemical properties in an electronic data base. The Company now has in the order of 14,000 isolates in two subzero libraries. These represent
Slide 6: Specialised culture medium and provisional patent
For personal use only This year this section finalised the development of a specialised culture medium that both enhances the amount of antibiotic that an actinomycete can produce and also enhances the variety of antibiotics produced. A Provisional Patent has been lodged for the medium and Actin
Slide 7: Antibiotic primary screening results
For personal use only 1526 isolates representing 7630 cultures were passed through primary screening . Approx. 691 of these showed antibiotic activity and moved forward to secondary screening. . 135 isolates showed antibiotic activity against the full panel of MRSA 64 isolates were active against th
Slide 8: Clostridium difficile screening
For personal use only Clostridium difficile is an anaerobic bacterium that is emerging as a significant pathogen for man and farm animals. This bacterium is also becoming resistant to currently used antibiotics. Actinogen has introduced a screening programme directed against this organism. 19 of 182
Slide 9: Dereplication against reference libraries
For personal use only Many bioactive molecules that we detect have been found before and these have to be excluded from further testing. Liquid chromatography and UV spectra of the culture media are compared to libraries of known substances Actinogen currently has a reference library containing some
Slide 10: Unidentified active isolates
For personal use only Currently Actinogen has 60 isolates active against MRSA that are not identified by the reference libraries. 30 isolates active against the Candida panel cannot be identified 21 isolates active against VRE and 2 isolates active against Pseudomonas aeruginosa also cannot be ident
Slide 11: UV peaks and expanding libraries
For personal use only Interesting UV peaks are present in the active isolates and it is from these that new antibiotic activity is most likely to be present. However, our identification procedures are limited by the extent of our reference libraries We continue to expand these libraries and we are a
Slide 12: Anti-cancer screening cultures
For personal use only Two groups of actinomycete cultures are used: [1] All cultures that have antibiotic activity which on dereplication do not have known anti cancer molecules present in our reference libraries. [2] All cultures that have no antibiotic activity and no anti cancer molecule profiles
Slide 13: Cancer cell line primary screening
For personal use only [1] Human adenocarcinoma of cervix: Hela [2]Human epithelial carcinoma of the lung: A549 [3] Murine spindle cell melanoma of skin: B16 [4] Neoplastic subcutaneous fibroblast from mouse: L929 Primary screening: 455 actinomycetes have been tested over 41,888 individual cultures f
Slide 14: Cytostatic and cytotoxic activity; macusolin
For personal use only After primary screening 128 isolates were shown to have either significant cytostatic or cytotoxic activity.12 isolates had activity against all the cell lines. Dereplication studies have detected a chemical known as MACUSOLIN in active cultures While this has been reported to
Slide 15: Tertiary screens for modes of action
For personal use only Tertiary screens are being developed to attempt to define the modes of action of active preparations from the actinomycetes. These include testing for: Apoptosis – lethal suicide induced in the target cell Anti-angiogenesis- factors that inactivate a tumour’s ability to develop
Slide 16: Candida albicans screening
For personal use only Candida albicans Fungal yeast infections caused by Candidas are widespread in humans especially in immune suppressed subjects. There are several species that cause serious disease in humans The majority of anti-Candida agents available are synthetic and toxic. 1526 new actinomy
Slide 17: Anti-Candida assay results
For personal use only A 96 well tray assay system was shown to eliminate volatile anti Candida molecules, which are commonly found to be active against yeasts. One isolate has been shown to remain active against the full panel of Candidas and one other was active against part of the panel. The isola
Slide 18: Anacardic acid discovery
For personal use only An anacardic acid An actinomycete isolate has been discovered that synthesizes an anacardic acid. The structure has been determined by mass spectrometry to be identical to the structure above.
Slide 19: Anacardic acid patent and commercial partners
For personal use only The synthesis of this anacardic acid by an actinomycete appears to be a rare event Actinogen has registered the actinomycete isolate under the terms of the Budapest Treaty which is a requirement for patenting procedures. Actinogen has taken out a Provisional Patent on the metho
Slide 20: Agriculture research areas
For personal use only FOUR AREAS HAVE BEEN INVESTIGATED: [1] Anti fungal activity for curly leaf [2] Search for actinomycetes that can live in high salt conditions [3] Discovery of two actinomycetes that can kill a brown rot fungus pathogenic to stone fruit [4] Discovery of two actinomycetes that pr
Slide 21: Brown rot of stone fruit
For personal use only Brown rot of stone fruit The fungus An actinomycete with strong anti fungal activity
Slide 22: Unidentified active molecule
For personal use only One of the two isolates is producing an unidentifiable active molecule. Further extensive tests using external library sources have so far not been able to identify the active molecule. Actinogen is now progressing to attempts to determine a structure for the active molecule. T
Slide 23: Plant growth hormone producers
For personal use only Dereplication located two actinomycetes that were producing plant growth hormones. Growth trials in petri dishes using wheat seeds indicated that the seeds grow faster in the presence of media from the isolates Out door pot trials using olive plantlets are in progress.
Slide 24: Cellulose and plastic digesting actinomycetes
For personal use only Actinomycete that Actinogen has isolated a digests cellulose number of actinomycetes that digest cellulose. Actinogen has also discovered a bacterium which has been classified as a Paenibacillus species.. This bacterium in cooperation with the actinomycetes leads to the digesti
Slide 25: Paper and plastic digestion areas
For personal use only Control Three areas have been investigated: [1] Digestion of cigarette paper [2] Digestion of brown Test paper bags [3] Digestion of “biodegradable” plastic bags
Slide 26: Paper digestion tests
For personal use only PAPER CONTROLS TESTS Bacterial growth and purple pigment production denotes utilization of paper as a nutrient source
Slide 27: Biodegradable plastic digestion tests
For personal use only Biodegradable plastic Control Bacterial growth and purple pigment Test indicate use of plastic as a nutrient source
Slide 28: Provisional patent for degradable bags
For personal use only Actinogen has filed a Provisional Patent for methodologies of incorporating bacterial isolates into the preparation of both paper and plastic bags that will aid the digestion of the bags on their disposal. Actinogen is currently seeking commercial interests to develop this are
Slide 29: Siderophores and iron recovery
For personal use only Iron is an absolute requirement for life to exist. Bacteria have developed methods that allow them to “search” for and recover iron from the environment. One of the most powerful mechanisms is through a group of complexes known as the Siderophores. .
Slide 30: Examples of siderophores
For personal use only Examples of siderophores Actinogen’s dereplication section has shown that the actinomycetes contain a number of siderophores and we have explored these for their capacities to trap iron molecules
Slide 31: Siderophore production and iron leaching patent
Twenty two actinomycetes have been shown to be capable of strong For personal use only siderophore production under iron starvation. However, siderophore activity is under strong iron ion control. The majority of siderophores produced were either catechols or hydroxamates. One isolate produced enter
Slide 32: Closing remarks and thank you
For personal use only I hope that I have indicated to you that Actinogen’s R&D programme is extremely active with several of its projects now under Provisional Patent and Budapest Treaty protection. Commercial interests are now being actively persued. Field sampling has been reduced this year as our
Actinogen Medical — Shareholder Meeting (November 2010) on 6ix